Important Information About EXKIVITY^® (mobocertinib)

Following discussions with the U.S. Food and Drug Administration (FDA), Takeda announced the initiation of the withdrawal of EXKIVITY (mobocertinib) on October 2, 2023.

The U.S. Food and Drug Administration (FDA) withdrew the US license for EXKIVITY on July 15, 2024.

For additional questions, please contact Takeda at 844-662-8532 between the hours of 8:00am and 6:00pm EST, or globaloncologymedinfo@takeda.com.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc.
at 1-844-217-6468 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch